Vivos Therapeutics Overview
Vivos Therapeutics (VVOS) has a ROE of 668.86%, above the Healthcare sector average of 21.28%.
Get informed when a big investor buys or sells
+ Follow668.86%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for VVOS is 668.86%. That is above the Healthcare sector average of 21.28%. Investors often review this figure alongside Vivos Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, VVOS currently prints 668.86% for ROE, while the sector average sits near 21.28%. That is roughly 3043.2% above the sector mean. Large gaps often invite a closer look at Vivos Therapeutics's growth, margins, and balance sheet.
Return on Equity shows how effectively Vivos Therapeutics converts resources into returns. At 668.86%, VVOS may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting VVOS's ROE (668.86%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Vivos Therapeutics's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
